|Bid||42.02 x 1000|
|Ask||42.03 x 4000|
|Day's Range||41.98 - 42.68|
|52 Week Range||33.20 - 46.47|
|Beta (3Y Monthly)||0.73|
|PE Ratio (TTM)||10.63|
|Forward Dividend & Yield||1.44 (3.39%)|
|1y Target Est||N/A|
—FDA grants a Priority Review based on Phase 3 ATTR-ACT study findings in ATTR-CM—
NEW YORK, NY / ACCESSWIRE / January 4, 2019 / U.S. markets plunged on Thursday, with the Dow Jones falling more than 600 points, as fears of a possibility of a global economic slowdown intensified after Apple lowered revenue forecasts. The Dow Jones Industrial Average dropped 2.83 percent to close at 22,686.22, dragged mostly lower by losses in Apple’s stock, while the S&P 500 Index decreased 2.48 percent to close at 2,447.89. The Nasdaq Composite Index slumped 3.04 percent to close at 6,463.50.
“We are proud to start this global pivotal Phase 2b/3 trial for PF-06651600 in patients with alopecia areata. Positive Phase 2a data for PF-06651600 was recently presented as a late-breaker at the 27th European Academy of Dermatology and Venerology (EADV).
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chief Operating Officer, and Mikael Dolsten, President, Worldwide Research and Development, at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 8:30 a.m. Pacific Standard Time. Effective January 1, 2019, Albert Bourla will become Chief Executive Officer. Information on accessing and pre-registering for the webcast will be available at www.pfizer.com/investors beginning today.
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chief Operating Officer, at the Goldman Sachs 11th Annual Healthcare CEOs Unscripted: A View from the Top on Thursday, January 3, 2019 at 10:15 a.m. Eastern Standard Time. Effective January 1, 2019, Albert Bourla will become Chief Executive Officer. Information on accessing and pre-registering for the webcast will be available at www.pfizer.com/investors beginning today.
DARMSTADT, Germany , and NEW YORK , December 21, 2018 /PRNewswire/ -- Not intended for UK-based media Merck KGaA, Darmstadt, Germany , and Pfizer Inc. (NYSE: PFE) today announced that data from a planned ...
Pfizer Inc. (PFE) announced today that the Phase 2b trial STRIVE (STaphylococcus aureus SuRgical Inpatient Vaccine Efficacy) evaluating the company’s investigational Staphylococcus aureus (S. aureus) multi-antigen vaccine (PF-06290510) is being discontinued due to futility. This decision is based on a recommendation from an independent Data Monitoring Committee (DMC), composed of external experts, after conducting a pre-planned interim analysis. A safety review by the DMC indicated that the investigational vaccine has been safe and well tolerated.
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (PFE) today announced that the Phase 3 ARCHES trial evaluating XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC) met its primary endpoint, significantly improving radiographic progression-free survival (rPFS) versus ADT alone. The preliminary safety analysis of the ARCHES trial appears consistent with the safety profile of XTANDI in previous clinical trials in castration-resistant prostate cancer (CRPC). “While XTANDI is currently approved for both metastatic and non-metastatic CRPC, there still remains a need for more treatment options for men with metastatic hormone-sensitive prostate cancer,” said Mace Rothenberg, M.D., Chief Development Officer, Oncology, Pfizer Global Product Development.
TOKYO and NEW YORK , Dec. 20, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") and Pfizer Inc. (NYSE: PFE) today announced that the ...
Pfizer Inc. (PFE) and GlaxoSmithKline plc (GSK) today announced they have entered into an agreement to create a premier global consumer healthcare company with robust iconic brands. The Boards of Directors of both companies have unanimously approved the transaction under which Pfizer will contribute its consumer healthcare business to GlaxoSmithKline’s existing consumer healthcare business.
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, January 29, 2019. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter 2018 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors.
Kineta Immuno-Oncology to receive $15 million upfront and will be eligible to receive up to $505 million in potential research, development and sales milestone payments Research collaboration focused on ...
The board of directors of Pfizer Inc. today declared a 36-cent first-quarter 2019 dividend on the company’s common stock, payable March 1, 2019, to shareholders of record at the close of business on February 1, 2019. Pfizer increased the dividend by approximately 6 percent, to 36 cents from 34 cents per share. The first-quarter 2019 cash dividend will be the 321st consecutive quarterly dividend paid by Pfizer.
ZIRABEV™ , a potential biosimilar to Avastin®* , is Pfizer’s second therapeutic oncology biosimilar to receive a positive CHMP opinion in Europe in 2018
Pfizer Inc. (PFE) announced today the initiation of a Phase 3 program for its 20-Valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077, for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine in adults aged 18 years and older. “While the full extent of Prevenar 13 protection of adults is still being realized, we anticipate our 20vPnC vaccine candidate will be the next important step to help protect adults from a substantial invasive pneumococcal disease and pneumonia burden, including disease caused by serotypes not yet covered by any available conjugate vaccine,” said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer.
NEW YORK, NY / ACCESSWIRE / December 14, 2018 / U.S. markets finished modestly higher on Thursday as investors continue to worry about trade tensions between the U.S. and China. The Dow Jones Industrial ...
NEW YORK, Dec. 12, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
NEW YORK, NY / ACCESSWIRE / December 5, 2018 / U.S. equities plunged on Tuesday as skepticism over the U.S. and China’s ability to close a trade agreement weighed on the markets. The Dow Jones Industrial ...
NEW YORK-- -- 26-week data from the ongoing 52-week REFLECTIONS B328-06 study met its primary endpoint, demonstrating comparable safety and efficacy for patients with indolent follicular lymphoma The U.S. Food and Drug Administration accepted for review, a Biologics License Application for PF-05280586 in September 2018 Pfizer Inc. announced today at the American Society of Hematology Annual Meeting ...
Pfizer Inc. (PFE) today announced that it has signed licensing agreements with AbbVie, resolving all global intellectual property matters for Pfizer’s proposed adalimumab biosimilar. Under the terms of the agreements, AbbVie grants Pfizer a non-exclusive patent license for the use and sale of Pfizer’s proposed adalimumab biosimilar for many countries around the world. Pfizer may launch its adalimumab biosimilar upon approval by the European Medicines Agency in Europe.
Pfizer Inc. (PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for LYRICA®. LYRICA is currently approved in the U.S. for fibromyalgia, diabetic nerve pain, spinal cord injury nerve pain and pain after shingles in adults. LYRICA is also approved as adjunctive therapy for the treatment of partial onset seizures in patients four years of age and older.
DAURISMO is the first and only Hedgehog pathway inhibitor approved for the treatment of AML
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Chris Boshoff, senior vice president and head, Immuno-Oncology, Early Development and Translational Oncology, at the Evercore ISI HealthConX Conference on Wednesday, November 28, 2018 at 8:45 a.m. EST. Information on accessing and pre-registering for the webcast will be available at www.pfizer.com/investors beginning today. Visitors will be able to listen to an archived copy of the webcast at www.pfizer.com/investors.
DARMSTADT, Germany and NEW YORK , November 19, 2018 /PRNewswire/ -- Not intended for UK-based media Merck KGaA, Darmstadt, Germany , and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN ...
NEW YORK, NY / ACCESSWIRE / November 19, 2018 / Pfizer and Facebook were both in deep water last week. Pharma giant Pfizer decided to increase the prices of 41 drugs according to the WSJ with the price hikes taking effect in January. Shares of Facebook hit a new low as Wall Street continued to grapple with a NY Times article about executives at the company ignoring warning signs of abuse.